Literature DB >> 28228461

Sex Differences in Inflammatory Markers and Health Status Among Young Adults With Acute Myocardial Infarction: Results From the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction Patients) Study.

Yuan Lu1, Shengfan Zhou1, Rachel P Dreyer1, Erica S Spatz1, Mary Geda1, Nancy P Lorenze1, Gail D'Onofrio1, Judith H Lichtman1, John A Spertus1, Paul M Ridker1, Harlan M Krumholz2.   

Abstract

BACKGROUND: Young women (≤55 years of age) with acute myocardial infarction (AMI) have higher mortality risk than similarly aged men. Elevated inflammatory markers are associated with an increased risk of cardiovascular outcomes after AMI, but little is known about whether young women have higher inflammatory levels after AMI compared with young men. METHODS AND
RESULTS: We assessed sex differences in post-AMI inflammatory markers and whether such differences account for sex differences in 12-month health status, using data from 2219 adults with AMI, 18 to 55 years of age, in the United States. Inflammatory markers including high-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 were measured 1 month after AMI. Overall, women had higher levels of hsCRP and lipoprotein-associated phospholipase A2 after AMI compared with men, and this remained statistically significant after multivariable adjustment. Regression analyses showed that elevated 1-month hsCRP was associated with poor health status (symptom, function, and quality of life) at 12 months. However, the association between hsCRP and health status became nonsignificant after adjustment for sociodemographics, comorbidities, and treatment factors. Half of these patients had residual inflammatory risk (hsCRP >3 mg/L) compared with a third who had residual cholesterol risk (Low-density lipoprotein cholesterol >100 mg/dL).
CONCLUSIONS: Young women with AMI had higher inflammatory levels compared with young men. Elevated 1-month hsCRP was associated with poor health status at 12 months after AMI, but this was attenuated after adjustment for patient characteristics. Targeted anti-inflammatory treatments are worthy of consideration for secondary prevention in these patients if ongoing trials of anti-inflammatory therapy prove effective.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  C-reactive protein; biomarkers; inflammation; myocardial infarction; women

Mesh:

Substances:

Year:  2017        PMID: 28228461      PMCID: PMC5459381          DOI: 10.1161/CIRCOUTCOMES.116.003470

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  21 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

3.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis
Journal:  Circulation       Date:  2012-08-24       Impact factor: 29.690

4.  Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III.

Authors:  N D Wong; J Pio; R Valencia; G Thakal
Journal:  Prev Cardiol       Date:  2001

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort.

Authors:  Susan G Lakoski; Mary Cushman; Michael Criqui; Tatjana Rundek; Roger S Blumenthal; Ralph B D'Agostino; David M Herrington
Journal:  Am Heart J       Date:  2006-09       Impact factor: 4.749

7.  Reliability and validity of the instrument used in BRFSS to assess physical activity.

Authors:  Michelle M Yore; Sandra A Ham; Barbara E Ainsworth; Judy Kruger; Jared P Reis; Harold W Kohl; Caroline A Macera
Journal:  Med Sci Sports Exerc       Date:  2007-08       Impact factor: 5.411

8.  Elevation of C-reactive protein in "active" coronary artery disease.

Authors:  B C Berk; W S Weintraub; R W Alexander
Journal:  Am J Cardiol       Date:  1990-01-15       Impact factor: 2.778

9.  Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Authors:  Erin A Bohula; Robert P Giugliano; Christopher P Cannon; Jing Zhou; Sabina A Murphy; Jennifer A White; Andrew M Tershakovec; Michael A Blazing; Eugene Braunwald
Journal:  Circulation       Date:  2015-09-01       Impact factor: 29.690

10.  Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease.

Authors:  J A Spertus; J A Winder; T A Dewhurst; R A Deyo; J Prodzinski; M McDonell; S D Fihn
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

View more
  12 in total

Review 1.  Premature Myocardial Infarction in the Middle East and North Africa: Rationale for the Gulf PREVENT Study.

Authors:  Sagar B Dugani; Waheed Murad; Karisamae Damilig; Jean Atos; Eshraga Mohamed; Edward Callachan; Zareen Farukhi; Arshia Shaikh; Abubaker Elfatih; Salwa Yusef; Yousif M Hydoub; M Vinayaga Moorthy; Bassem Mora; Ahlam Alawadhi; Robin Issac; Abdulkarim Saleh; Arif Al-Mulla; Samia Mora; Alawi A Alsheikh-Ali
Journal:  Angiology       Date:  2019-05-26       Impact factor: 3.619

Review 2.  Unique Presentations and Etiologies of Myocardial Infarction in Women.

Authors:  Marysia S Tweet; Patricia Best; Sharonne N Hayes
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-09

3.  Cytokines are associated with longitudinal changes in cognitive performance among urban adults.

Authors:  May A Beydoun; Jordan Weiss; Hardeep K Obhi; Hind A Beydoun; Gregory A Dore; Hailun Liang; Michele K Evans; Alan B Zonderman
Journal:  Brain Behav Immun       Date:  2019-04-11       Impact factor: 7.217

Review 4.  Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications.

Authors:  Emily S Lau; Aleksandra Binek; Sarah J Parker; Svati H Shah; Markella V Zanni; Jennifer E Van Eyk; Jennifer E Ho
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

5.  Prevalence and predictors of elevated high-sensitivity C-reactive protein in post-myocardial infarction patients: Insights from the VIRGO and TRIUMPH registries.

Authors:  Mohammed Qintar; Puza P Sharma; Yashashwi Pokharel; Yuanyuan Tang; Yuan Lu; Philip Jones; Rachel P Dreyer; John A Spertus
Journal:  Clin Cardiol       Date:  2017-12-16       Impact factor: 2.882

6.  Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins.

Authors:  Hayder M Alkuraishy; Ali I Al-Gareeb; Huda J Waheed
Journal:  J Neurosci Rural Pract       Date:  2018 Oct-Dec

7.  Keratin 8 is a potential self-antigen in the coronary artery disease immunopeptidome: A translational approach.

Authors:  Peter M Mihailovic; Wai Man Lio; Romana Herscovici; Kuang-Yuh Chyu; Juliana Yano; Xiaoning Zhao; Jianchang Zhou; Bo Zhou; Michael R Freeman; Wei Yang; Prediman K Shah; Bojan Cercek; Paul C Dimayuga
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

8.  Systemic Inflammation Is Associated With Longitudinal Changes in Cognitive Performance Among Urban Adults.

Authors:  May A Beydoun; Gregory A Dore; Jose-Atilio Canas; Hailun Liang; Hind A Beydoun; Michele K Evans; Alan B Zonderman
Journal:  Front Aging Neurosci       Date:  2018-10-09       Impact factor: 5.750

Review 9.  Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications.

Authors:  Antonio V Sterpetti
Journal:  Curr Atheroscler Rep       Date:  2020-10-06       Impact factor: 5.113

Review 10.  Inflammation and cardiovascular disease: From mechanisms to therapeutics.

Authors:  Abdulhamied Alfaddagh; Seth S Martin; Thorsten M Leucker; Erin D Michos; Michael J Blaha; Charles J Lowenstein; Steven R Jones; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2020-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.